Answers are grounded in this paper and cite their sources.
AIM:To identify the persistence of immune protection of China-made, plasma derived hepatitis B vaccine after infancy immunization and the time table of booster immunization.METHODS:A cross-sectional follow-up study and an experimental study on booster were used for the evaluation of the serological effect 7 years after vaccination and the antibody anamnestic response. Radioimmunoassay was used for the detection of hepatitis B virus markers. RESULTS:The protective anti-HBs positive rates of 1018 children, who were vaccinated according to the regimen of three doses of 10 g hepatitis B vaccine in their infancy, declined from 75.0% during the first two years to 48.2% in the 7th year after the first dosage, however, the positive rates for HBsAg and anti-HBc always fluctuated at a low frequency. A total of 144 subjects aged 6 or 7 years, who were negative for both HBsAg and anti-HBc before booster, were selected from 1018 children of the follow-up study, and boosted with 1g intradermally or 2g hypodermically hepatitis B vaccines. Their anti-HBs GMT and anti-HBs positive rates were 190.6mIU/ml and 89.6% in the first month after booster,significantly higher than 14.7mIU/ml and 54.9% before booster (P < 0.01), and declined back to 25.3mIU/ml and 75.5% in the 12th month; among 65 children with the anti-HBs negative before booster, 40 had a level of anti-HBS< = 100mIU/ml one month after booster, suggesting retention of immune memory in most of them.CONCLUSION:No need for revaccination against hepatitis B in the 7th year after the initial immunization due to better persistence of immune protection of the vaccine and retention of immune memory to hepatitis B virus in the vast majority of the vaccinees.
No takes yet. Share an insight, caveat, or question.
Hui Li (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: